Lilly liver cancer drug fails Phase 3 trial

|By:, SA News Editor

In a Phase 3 study, Eli Lilly's (LLY) orphan drug-designated liver cancer product candidate Cyramza (ramucirumab) failed to meet its primary endpoint of a statistically significant improvement in overall survival (OS). The trial compared Cyramza plus best supportive care to placebo plus best supportive care as a second-line treatment in patients with hepatocellular carcinoma (HCC) after being treated with sorafenib as a first-line therapy.

SVP, Product Development and Medical Affairs for Lilly Oncology, Richard Gaynor, M.D., says, "Although the REACH study did not achieve statistical significance for survival, we are encouraged by the efficacy seen overall, especially in specific subpopulations. We plan to discuss these results with regulatory authorities."